Search Results for "danazol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for danazol. Results 1 to 2 of 2 total matches.
Lanadelumab (Takhzyro) for Prevention of Hereditary Angioedema (online only)
The Medical Letter on Drugs and Therapeutics • Mar 11, 2021 (Issue 1619)
long-term
prophylaxis with a human plasma-derived C1INH, an
oral attenuated androgen such as danazol ...
The FDA has approved lanadelumab-flyo (Takhzyro –
Takeda), a subcutaneously-administered plasma
kallikrein inhibitor, for prevention of hereditary
angioedema (HAE) attacks in adults and children
≥12 years old. Lanadelumab is the third drug to be
approved for this indication; the human plasmaderived
C1 esterase inhibitors (C1INHs) Cinryze,
which is administered IV, and Haegarda, which is
given SC, have been available for years for HAE
prophylaxis in patients ≥6 years old.
Berotralstat (Orladeyo) for Prevention of Hereditary Angioedema (online only)
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
with a human plasma-derived
C1INH, an oral attenuated androgen such as danazol,
an oral antifibrinolytic drug ...
Berotralstat (Orladeyo – Biocryst), an oral plasma
kallikrein inhibitor, has been approved by the FDA
for prevention of hereditary angioedema (HAE)
attacks in adults and children ≥12 years old. The
subcutaneously-injected plasma kallikrein inhibitor
lanadelumab-flyo (Takhzyro) and the human plasma-derived
C1 esterase inhibitors (C1INHs) Cinryze, which
is given IV, and Haegarda, which is given SC, have been
available for prophylaxis of HAE for years.